seed
Stage
3
Investors
About
Enodia Therapeutics is a French biotech company developing small-molecule therapies for targeted protein degradation at the point of protein synthesis by targeting the Sec61 translocon, a cellular gateway for secreted and membrane proteins.
Explore Enodia Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.